4AA Preclinical
Bronchogen
Synthetic bronchial tetrapeptide (Ala-Glu-Asp-Leu, AEDL) from the Khavinson school that stabilises bronchial epithelial DNA, restores ciliated cell populations, and reduces neutrophilic inflammation in preclinical COPD and fibrosis models.
In Plain English:
Bronchogen is a four-amino-acid chain (alanine – glutamic acid – aspartic acid – leucine, AEDL) isolated from murine bronchial mucosa and developed into a synthetic bioregulator by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. In animal models it reverses several hallmarks of chronic obstructive pulmonary disease: goblet-cell hyperplasia, squamous metaplasia, lymphocytic infiltration, and emphysematous changes are all reduced after one month of treatment in NO₂-induced COPD rats. At the molecular level it binds within the major groove of DNA at the guanine N7 site without distorting the double helix, raises DNA melting temperature by 3.1 °C (evidence of strand stabilisation), and activates transcription factors critical for bronchial identity — Nkx2.1, FoxA1, FoxA2 — alongside secretoglobin genes SCGB1A1 and SCGB3A2. It also elevates secretory IgA in bronchoalveolar lavage, supporting mucosal immunity. The full human clinical evidence base is thin: Russian supplement-approval research and one observational study co-administering Bronchogen with the companion bronchial tripeptide Chonluten (EDG); no blinded, randomised, placebo-controlled trial has been published. Outside Russia it is sold as a research-grade lyophilised peptide or imported as the oral capsule form produced by PeptidBio (formerly Cytogens).
Research Maturity
Preclinical (~8–12 peer-reviewed papers (2011–2020), mostly preclinical; no RCTs or independent replication+ Studies)
Origin
Developed at the St. Petersburg Institute of Bioregulation and Gerontology (Russia) by V.Kh. Khavinson and colleagues; derived from the polypeptide extract of bovine/murine bronchial mucosa designated complex AC-11, later synthesised as the isolated tetrapeptide AEDL. First formal publication on DNA thermostability appeared in 2011 (PMID 21240358); gene-expression work in bronchial epithelial culture followed in 2014 (PMID 25015171); DNA-interaction spectroscopy published in 2017 (Journal of Structural Chemistry, doi 10.1134/S0022476617020299). Marketed under the brand name Bronchogen® by Peptid Bio LLC (St. Petersburg); same compound is sold as synthesised research peptide globally.
Mechanism
Bronchogen exerts its effects at the level of gene regulation rather than classical receptor agonism. Key documented mechanisms: (1) DNA groove binding — UV spectrophotometry, circular dichroism, and viscosimetry show AEDL forms a complex with DNA via the major furrow at guanine N7 without distorting the double helix, providing access to regulatory sequences without strand damage; (2) DNA thermostabilisation — raises melting temperature of both calf thymus and mouse liver DNA by 3.1 °C across molar ratios 0.01–0.055, with constant melting enthalpy, indicating non-selective stabilising interaction with nitrogen bases; (3) transcription factor activation — upregulates bronchial master regulators Nkx2.1, FoxA1, FoxA2 and secretoglobins SCGB1A1 and SCGB3A2, which are essential for bronchial epithelial identity, mucociliary function, and surfactant homeostasis; (4) protein-level regulation — modulates Ki67 (proliferation), Mcl-1 (anti-apoptotic), p53 (tumour suppressor), CD79 (immune signalling), NOS-3 (vascular/NO), MUC4 and MUC5AC (mucin production), and SftpA1 (surfactant protein A); (5) histone interaction — engages core histones H1, H2B, H3, H4, consistent with chromatin-remodelling activity reported across other Khavinson tetrapeptides; (6) anti-inflammatory tissue repair — in NO₂-COPD rat model reverses goblet-cell hyperplasia, squamous metaplasia, emphysema, lymphocytic infiltration, and neutrophilic bronchoalveolar cell profiles; reduces TNF-α and IL-8 in bronchoalveolar lavage; (7) immune restoration — increases secretory IgA in bronchoalveolar fluid, reinforcing the mucosal immune barrier; (8) surfactant support — elevates surfactant protein B (reduces alveolar surface tension); (9) geroprotective bias — proliferation and differentiation marker responses are strongest in aged cell cultures, consistent with the broader Khavinson hypothesis that short peptides reverse age-related gene silencing.
Outcome
Reversal of COPD histopathology (goblet-cell hyperplasia, squamous metaplasia, emphysema, lymphocytic infiltration) in NO₂-exposed rat model; restoration of ciliated bronchial epithelial cells; reduced neutrophilic inflammation in bronchoalveolar lavage; decreased pro-inflammatory cytokines TNF-α and IL-8; increased secretory IgA in bronchoalveolar lavage; increased surfactant protein B; DNA melting temperature raised +3.1 °C (thermostabilisation); upregulation of Nkx2.1, SCGB1A1, SCGB3A2, FoxA1, FoxA2, Hoxa3 (1.4–1.7× in aged cultures); modulation of Ki67, Mcl-1, p53, CD79, NOS-3, MUC4, MUC5AC, SftpA1; cell proliferation stimulation strongest in aged passage cultures (geroprotective signal). Clinical/observational: improved FEV1 and FVC spirometry in Russian COPD/chronic-bronchitis patients receiving Bronchogen + Chonluten combination; no standalone human RCT outcome data available.
